Published in Endocr Relat Cancer on June 01, 2003
Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One (2010) 6.61
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A (2004) 2.64
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol (2007) 2.14
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol (2006) 1.88
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem (2011) 1.82
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.69
Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Res (2007) 1.63
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res (2004) 1.52
Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer (2011) 1.51
Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol (2004) 1.40
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 1.36
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res (2006) 1.35
Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation. J Biol Chem (2009) 1.29
Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell (2009) 1.17
CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res (2011) 1.06
CCCTC-binding factor acts upstream of FOXA1 and demarcates the genomic response to estrogen. J Biol Chem (2010) 1.04
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res (2010) 1.03
Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer (2010) 1.03
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene (2015) 1.03
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene (2008) 1.02
PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J Clin Invest (2007) 1.00
Mammographic density and epithelial histopathologic markers. BMC Cancer (2009) 1.00
SIP, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasm. EMBO J (2007) 1.00
Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. PLoS One (2010) 0.99
Induction of G1 cell cycle arrest and cyclin D1 down-regulation in response to pericarp extract of Baneh in human breast cancer T47D cells. Daru (2012) 0.96
Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer (2010) 0.93
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res (2011) 0.92
Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. Cancer Res (2007) 0.92
Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. Int J Clin Exp Pathol (2009) 0.91
Human SWI/SNF drives sequence-directed repositioning of nucleosomes on C-myc promoter DNA minicircles. Biochemistry (2007) 0.90
GAS, a new glutamate-rich protein, interacts differentially with SRCs and is involved in oestrogen receptor function. EMBO Rep (2008) 0.90
Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells. Horm Cancer (2010) 0.88
Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines. BMC Cancer (2009) 0.87
Cyclin D1 regulates hepatic estrogen and androgen metabolism. Am J Physiol Gastrointest Liver Physiol (2010) 0.87
Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer (2008) 0.87
Influence of fatty acid diets on gene expression in rat mammary epithelial cells. Physiol Genomics (2009) 0.84
Highly sensitive quantitative imaging for monitoring single cancer cell growth kinetics and drug response. PLoS One (2014) 0.84
RB·E2F1 complex mediates DNA damage responses through transcriptional regulation of ZBRK1. J Biol Chem (2010) 0.84
Estradiol downregulation of the tumor suppressor gene BTG2 requires estrogen receptor-alpha and the REA corepressor. Int J Cancer (2009) 0.84
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. BMC Cancer (2014) 0.83
Combination treatment of tamoxifen with risperidone in breast cancer. PLoS One (2014) 0.83
Apoptosis and autophagy in breast cancer cells following exemestane treatment. PLoS One (2012) 0.82
Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci (2008) 0.82
Association between melanocytic nevi and risk of breast diseases: The French E3N prospective cohort. PLoS Med (2014) 0.82
The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol (2009) 0.79
Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells. BMC Cancer (2014) 0.78
17β-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells. Oncotarget (2014) 0.77
Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. Breast Cancer Res (2012) 0.77
Estrogen induces Vav1 expression in human breast cancer cells. PLoS One (2014) 0.76
New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. BMC Cell Biol (2008) 0.76
Estrogen receptor alpha inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells. Oncotarget (2016) 0.75
Endogenous sex hormones and breast density in young women. Cancer Epidemiol Biomarkers Prev (2014) 0.75
Ensemble classifier based on context specific miRNA regulation modules: a new method for cancer outcome prediction. BMC Bioinformatics (2013) 0.75
The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance. Oncotarget (2017) 0.75
Regulation of steroid hormone receptors and coregulators during the cell cycle highlights potential novel function in addition to roles as transcription factors. Nucl Recept Signal (2016) 0.75
Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle (2016) 0.75
Physical Activity in the Prevention and Therapy of Breast Cancer. Breast Care (Basel) (2010) 0.75
Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells. Oncogenesis (2017) 0.75
Maternal peripheral blood natural killer cells incorporate placenta-associated microRNAs during pregnancy. Int J Mol Med (2015) 0.75
Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival. Cell Cycle (2016) 0.75
Cell Growth of BG-1 Ovarian Cancer Cells was Promoted by 4-Tert-octylphenol and 4-Nonylphenol via Downregulation of TGF-β Receptor 2 and Upregulation of c-myc. Toxicol Res (2011) 0.75
Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer. J Mol Cell Biol (2015) 0.75
PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells. J Cancer Res Clin Oncol (2010) 0.75
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem (1983) 9.40
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem (1997) 2.40
Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A (1994) 2.29
Progestin regulation of cellular proliferation. Endocr Rev (1990) 2.04
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol (1998) 1.97
Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res (2001) 1.77
Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol (1999) 1.70
Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol (1993) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res (1983) 1.65
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs. Oncogene (1998) 1.56
Cloning and characterization of GRB14, a novel member of the GRB7 gene family. J Biol Chem (1996) 1.52
Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol (1983) 1.49
Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res (1988) 1.47
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol (2012) 1.46
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene (1994) 1.44
Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (2012) 1.44
Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol (1998) 1.42
Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res (2001) 1.40
Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res (1999) 1.39
Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res (1999) 1.39
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res (1985) 1.37
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol (1995) 1.35
A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem (2000) 1.34
Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res (2001) 1.32
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol (1991) 1.30
High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature (1980) 1.29
Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene (2007) 1.28
Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia (1998) 1.26
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol (2000) 1.22
Safety and effectiveness of placement of pacemaker and defibrillator leads in the axillary vein guided by contrast venography. Am J Cardiol (1997) 1.20
Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol (1998) 1.20
A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 1.15
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer (2011) 1.15
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene (2009) 1.15
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene (1998) 1.15
A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene (2009) 1.15
A new human breast carcinoma cell line (PMC42) with stem cell characteristics. III. Hormone receptor status and responsiveness. J Natl Cancer Inst (1984) 1.14
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol (2001) 1.13
Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res (1998) 1.13
Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene (1994) 1.12
DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer (2008) 1.11
Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem (1997) 1.10
Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res (1992) 1.10
Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther (2007) 1.10
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer (2000) 1.09
The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle. J Physiol (2000) 1.09
The influence of age on the DNA ploidy levels of breast tumours. Eur J Cancer Clin Oncol (1983) 1.09
Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7. J Biol Chem (1997) 1.08
Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res (1983) 1.08
EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene (1997) 1.08
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab (1997) 1.07
Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat (1994) 1.07
Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res (1997) 1.06
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene (2012) 1.06
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene (1998) 1.05
Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene (1998) 1.04
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer (1995) 1.04
Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res (1996) 1.04
Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer (1997) 1.03
Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res (2000) 1.02
Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res (1983) 1.02
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer (2008) 1.02
Cell cycle control by steroid hormones. Semin Cancer Biol (1994) 1.02
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res (2001) 1.02
Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer (1996) 1.00
Mechanisms of oestrogen antagonism by nonsteroidal antioestrogens. Mol Cell Endocrinol (1982) 0.99
Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. Biochem Biophys Res Commun (1986) 0.99
Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens (2001) 0.99
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer (2000) 0.98
Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res (1989) 0.98
Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res (1996) 0.97
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer (2005) 0.97
Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res (1993) 0.97
Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur J Cancer Clin Oncol (1983) 0.97
Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res (1984) 0.96